Maria Eugenia Alonso Ferrero

Maria Eugenia Alonso Ferrero has a diverse work experience spanning various roles and companies. Maria Eugenia began their career as a Pre-Doctoral Researcher at Universidad de León in 2000 and later worked as a Research Scientist at CIEMAT from 2003 to 2010. Maria Eugenia then joined UCL (Institute of Child Health) as a Research Associate from 2010 to 2015.

In 2015, Maria Eugenia joined GSK and served as an Investigator and Biology Lead for the development of new CAR-T cell technologies for solid tumors. Maria Eugenia coordinated technical units, represented the company in the NonGxP Data Integrity Council, and supervised apprentices.

In 2018, they moved to GammaDelta Therapeutics, where they worked as a Group Leader in immunotherapy. Maria Eugenia'sresponsibilities involved leading a project in collaboration with industrial and academic partners, establishing timelines and resources, designing and supervising experiments, and supporting process development and gene engineering teams.

Currently, Maria Eugenia works at Quell Therapeutics. Maria Eugenia started as a Molecular Biology & New Technologies Group Leader in 2019 and later became the Discovery & New Technologies Group Leader-Associate Director in 2020. As of October 2021, they hold the position of Science Strategy Associate Director.

Maria Eugenia Alonso Ferrero completed their education in a chronological order as follows:

From 1995 to 2000, they attended Universidad de León and obtained a Bachelor's degree in Fundamental Biology.

From 2000 to 2002, they pursued a Master's degree in Cell Biology at the same institution, Universidad de León.

Lastly, from 2003 to 2009, Maria Eugenia Alonso Ferrero pursued their Doctor of Philosophy (PhD) at Universidad Complutense de Madrid. Maria Eugenia'sresearch focused on the development of new gene and cell therapies for genetic diseases.